📊 AI Stock Rating — Summary

Acadia Healthcare (ACHC) reported Q3 2025 revenue of $851.6 million, with a net income of $36.2 million resulting in an EPS of $0.40. The company's free cash flow was a robust $73.2 million, reflecting effective cash management practices without capital expenditures in the quarter. Although year-over-year revenue growth appears stable, profitability shows room for improvement with a net margin of approximately 4.3%. The balance sheet is strong with total assets of $6.41 billion against total liabilities of $3.12 billion, although leverage is notable with net debt standing at $2.33 billion. While no dividends or stock buybacks were reported, analysts' price targets ranging from $22 to $35 suggest potential upside depending on strategic execution and market conditions. Despite these operational insights, no information about 1-year or specific short-term share price changes was provided to assess shareholder return, which remains a gap for this evaluation.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue growth is steady with $851.6 million reported, driven primarily by consistent demand. However, growth pace needs acceleration to appeal to growth-oriented investors.

Profitability — Score: 5/10

Net margin of 4.3% and EPS of $0.40 indicate moderate profitability. Operational efficiency can be enhanced to improve margins.

Cash Flow Quality — Score: 7/10

Strong free cash flow of $73.2 million with zero capex signals good liquidity. Absence of dividends or buybacks limits uses of cash flow but maintains inherent flexibility.

Leverage & Balance Sheet — Score: 5/10

Net debt of $2.33 billion represents significant leverage, though balanced by a strong equity position of $3.29 billion. Careful debt management will be essential for financial resilience.

Shareholder Returns — Score: 5/10

Without recent share price performance data or dividends, shareholder returns are strictly from potential equity appreciation, as suggested by varying analyst price targets.

Analyst Sentiment & Valuation — Score: 6/10

Analyst price targets up to $35 offer potential upside, suggesting the stock is fairly valued compared to its current price range.

⚠ AI-generated — informational only, not financial advice.